Arvinas, Inc (ARVN) Stock Price

ARVNStock

$9.60+27.60%52W

Market Cap$619.40M

P/E—

PEG Ratio—

Div yield—

Beta1.78

ARVN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.23%

Price vs S&P 500 (4W)10.85%

VGM Score62.89

Book Value / Share (Quarterly)$8.61

P/TBV (Annual)2.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.96%

Cash Flow / Share (Quarterly)$-3.20

Price vs S&P 500 (YTD)-33.21%

Net Profit Margin (TTM)2.94%

EPS (TTM)$0.16

10-Day Avg Trading Volume0.62M

EPS Excl Extra (TTM)$0.16

Revenue Growth (5Y)64.50%

EPS (Annual)$-1.14

ROI (Annual)-18.60%

Net Profit Margin (5Y Avg)-239.63%

Cash / Share (Quarterly)$8.70

P/E Basic Excl Extra (TTM)62.96x

Revenue Growth QoQ (YoY)1014.73%

ROA (Last FY)-11.26%

Revenue Growth TTM (YoY)-15.05%

EBITD / Share (TTM)$-0.23

ROE (5Y Avg)-36.82%

Operating Margin (TTM)-5.72%

Cash Flow / Share (Annual)$-4.34

P/B Ratio1.04x

P/B Ratio (Quarterly)0.95x

Net Income / Employee (Annual)$-328,500

EV / Revenue (TTM)1.55x

Net Interest Coverage (TTM)-2.48x

ROA (TTM)1.29%

EPS Incl Extra (Annual)$-1.14

Current Ratio (Annual)4.92x

Quick Ratio (Quarterly)7.54x

3-Month Avg Trading Volume0.83M

52-Week Price Return27.60%

P/E Incl Extra (TTM)62.96x

Revenue / Employee (TTM)$1,287,400

Tangible BV / Share (Quarterly)$8.31

P/S Ratio (Annual)2.23x

Asset Turnover (Annual)0.37x

52-Week High$14.51

Operating Margin (5Y Avg)-254.02%

EPS Excl Extra (Annual)$-1.14

CapEx CAGR (5Y)-21.56%

Tangible BV CAGR (5Y)370.17%

26-Week Price Return-20.98%

Quick Ratio (Annual)4.85x

13-Week Price Return2.64%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.91x

Enterprise Value$491.53M

Revenue / Share Growth (5Y)46.34%

Asset Turnover (TTM)0.44x

Book Value / Share Growth (5Y)-12.40%

Revenue / Employee (Annual)$1,067,500

Pretax Margin (Annual)-30.65%

Cash / Share (Annual)$10.79

3-Month Return Std Dev48.36%

Net Income / Employee (TTM)$37,800

ROE (Last FY)-18.62%

EPS Basic Excl Extra (Annual)$-1.14

P/FCF (TTM)11.76x

Receivables Turnover (TTM)12.47x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.16

Receivables Turnover (Annual)78.39x

ROI (TTM)1.91%

P/S Ratio (TTM)1.85x

Pretax Margin (5Y Avg)-233.90%

Revenue / Share (Annual)$3.70

Tangible BV / Share (Annual)$10.62

Forward P/E853.75x

Price vs S&P 500 (52W)9.29%

P/E Ratio (TTM)62.96x

Year-to-Date Return-21.25%

5-Day Price Return0.86%

EPS Normalized (Annual)$-1.14

ROA (5Y Avg)-18.40%

Net Profit Margin (Annual)-30.77%

Month-to-Date Return16.31%

Cash Flow / Share (TTM)$-5.17

EBITD / Share (Annual)$-1.63

Operating Margin (Annual)-45.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-36.77%

P/E Excl Extra (TTM)62.96x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.16

P/TBV (Quarterly)2.63x

P/B Ratio (Annual)1.76x

Pretax Margin (TTM)3.19%

Book Value / Share (Annual)$6.83

Price vs S&P 500 (13W)-0.16%

Beta1.78x

P/FCF (Annual)1.06x

Revenue / Share (TTM)$4.82

ROE (TTM)1.91%

52-Week Low$6.97

vGradeB

gGradeB

mGradeC

vgmGradeB

ARVN Earnings Surprise History

Q2 25-0.84est. -0.89

Q3 25-0.48est. -0.74

Q4 25-1.10est. -0.57

Q1 26-0.90est. -0.96

Q2 262.58est. -0.28

ARVN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.81

3.79

3.74

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARVNArvinas, Inc	B	B	C	$9.60
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Arvinas, Inc

Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies using its proprietary PROTAC platform, which harnesses the body's natural protein disposal system. The company is advancing a pipeline of clinical-stage candidates in oncology and neurology, including ARV-102, ARV-806, vepdegestrant, and others. The PROTAC approach offers a potentially differentiated mechanism for selectively eliminating disease-causing proteins.